JP2011509949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509949A5 JP2011509949A5 JP2010542509A JP2010542509A JP2011509949A5 JP 2011509949 A5 JP2011509949 A5 JP 2011509949A5 JP 2010542509 A JP2010542509 A JP 2010542509A JP 2010542509 A JP2010542509 A JP 2010542509A JP 2011509949 A5 JP2011509949 A5 JP 2011509949A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- halo
- alkyl
- subject
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 125000001475 halogen functional group Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- -1 trifluoro Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- 230000005907 cancer growth Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 230000001613 neoplastic effect Effects 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2224708P | 2008-01-18 | 2008-01-18 | |
| US61/022,247 | 2008-01-18 | ||
| PCT/CZ2009/000004 WO2009089804A1 (en) | 2008-01-18 | 2009-01-15 | Novel cytostatic 7-deazapurine nucleosides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013266910A Division JP2014058567A (ja) | 2008-01-18 | 2013-12-25 | 新規な細胞増殖抑制性７−デアザプリンヌクレオシド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509949A JP2011509949A (ja) | 2011-03-31 |
| JP2011509949A5 true JP2011509949A5 (enExample) | 2013-02-21 |
| JP5485172B2 JP5485172B2 (ja) | 2014-05-07 |
Family
ID=40434932
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010542509A Active JP5485172B2 (ja) | 2008-01-18 | 2009-01-15 | 新規な細胞増殖抑制性７−デアザプリンヌクレオシド |
| JP2013266910A Withdrawn JP2014058567A (ja) | 2008-01-18 | 2013-12-25 | 新規な細胞増殖抑制性７−デアザプリンヌクレオシド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013266910A Withdrawn JP2014058567A (ja) | 2008-01-18 | 2013-12-25 | 新規な細胞増殖抑制性７−デアザプリンヌクレオシド |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8093226B2 (enExample) |
| EP (2) | EP3133080B1 (enExample) |
| JP (2) | JP5485172B2 (enExample) |
| CN (1) | CN101977923B (enExample) |
| AU (1) | AU2009204568B2 (enExample) |
| CA (1) | CA2711384C (enExample) |
| CY (2) | CY1118104T1 (enExample) |
| DK (2) | DK3133080T3 (enExample) |
| ES (2) | ES2598503T3 (enExample) |
| HR (2) | HRP20161344T1 (enExample) |
| HU (2) | HUE041598T2 (enExample) |
| LT (2) | LT2231689T (enExample) |
| NZ (1) | NZ586610A (enExample) |
| PL (2) | PL2231689T3 (enExample) |
| PT (2) | PT3133080T (enExample) |
| SI (2) | SI3133080T1 (enExample) |
| TR (1) | TR201815961T4 (enExample) |
| WO (1) | WO2009089804A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3184526T3 (en) | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| EP2421879B1 (en) * | 2009-04-22 | 2013-09-04 | Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. | Novel 7-deazapurine nucleosides for therapeutic uses |
| ES2487542T3 (es) * | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
| WO2010135621A1 (en) * | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| SMT201800137T1 (it) | 2010-03-10 | 2018-07-17 | Incyte Holdings Corp | Derivati di piperidin-4-il azetidina come inibitori di jak1 |
| PH12012502296B1 (en) | 2010-05-21 | 2017-10-06 | Incyte Holdings Corp | Topical formulation for a jak inhibitor |
| CN103221048A (zh) * | 2010-11-18 | 2013-07-24 | 卡斯纳莱拉创新药物私人有限公司 | 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法 |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| PE20151157A1 (es) | 2012-11-15 | 2015-08-19 | Incyte Corp | Formas de dosificacion de ruxolitinib de liberacion sostenida |
| LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
| UA120499C2 (uk) | 2013-08-07 | 2019-12-26 | Інсайт Корпорейшн | Лікування захворювань із застосуванням лікарських форм з уповільненим вивільненням для інгібітора jak1 |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| WO2018001393A1 (en) | 2016-06-29 | 2018-01-04 | Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. | Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use |
| CZ307334B6 (cs) | 2016-08-02 | 2018-06-13 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| IL276302B2 (en) | 2018-01-30 | 2023-11-01 | Incyte Corp | Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one) |
| CZ308104B6 (cs) | 2018-03-12 | 2020-01-08 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. | Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| EP3952874A4 (en) * | 2019-04-05 | 2022-12-28 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 |
| JP7354246B2 (ja) * | 2019-06-18 | 2023-10-02 | 大鵬薬品工業株式会社 | ピロロピリミジン骨格を有する新規なリン酸エステル化合物又はその薬学的に許容可能な塩 |
| WO2021164848A1 (en) * | 2020-02-17 | 2021-08-26 | Katholieke Universiteit Leuven | Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN112190590A (zh) * | 2020-11-06 | 2021-01-08 | 牡丹江医学院 | 一种治疗动脉粥样硬化的硒核苷及其药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50125033A (enExample) * | 1974-03-19 | 1975-10-01 | ||
| IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| JPH10158293A (ja) * | 1996-08-08 | 1998-06-16 | Rikagaku Kenkyusho | ３’−デオキシリボヌクレオチド誘導体 |
| JP3318579B2 (ja) * | 1997-07-07 | 2002-08-26 | 理化学研究所 | Ｄｎａの塩基配列決定方法 |
| JP3489991B2 (ja) * | 1997-07-07 | 2004-01-26 | 理化学研究所 | ３’−デオキシリボヌクレオチド誘導体 |
| CZ9901996A3 (cs) * | 1999-06-04 | 2001-01-17 | Ústav organické chemie a biochemie AV ČR | Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují |
| WO2003051899A1 (en) * | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
| KR20060123707A (ko) * | 2003-08-27 | 2006-12-04 | 바이오타, 인코포레이티드 | 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드 |
| WO2006065335A2 (en) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| WO2006116557A1 (en) * | 2005-04-25 | 2006-11-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
-
2009
- 2009-01-15 PT PT16174985T patent/PT3133080T/pt unknown
- 2009-01-15 HR HRP20161344TT patent/HRP20161344T1/hr unknown
- 2009-01-15 LT LTEP09702842.7T patent/LT2231689T/lt unknown
- 2009-01-15 LT LTEP16174985.8T patent/LT3133080T/lt unknown
- 2009-01-15 AU AU2009204568A patent/AU2009204568B2/en active Active
- 2009-01-15 JP JP2010542509A patent/JP5485172B2/ja active Active
- 2009-01-15 PL PL09702842T patent/PL2231689T3/pl unknown
- 2009-01-15 NZ NZ586610A patent/NZ586610A/xx unknown
- 2009-01-15 EP EP16174985.8A patent/EP3133080B1/en active Active
- 2009-01-15 TR TR2018/15961T patent/TR201815961T4/tr unknown
- 2009-01-15 WO PCT/CZ2009/000004 patent/WO2009089804A1/en not_active Ceased
- 2009-01-15 HU HUE16174985A patent/HUE041598T2/hu unknown
- 2009-01-15 US US12/354,432 patent/US8093226B2/en active Active
- 2009-01-15 PL PL16174985T patent/PL3133080T3/pl unknown
- 2009-01-15 DK DK16174985.8T patent/DK3133080T3/en active
- 2009-01-15 HU HUE09702842A patent/HUE030767T2/en unknown
- 2009-01-15 SI SI200931882T patent/SI3133080T1/sl unknown
- 2009-01-15 SI SI200931535A patent/SI2231689T1/sl unknown
- 2009-01-15 DK DK09702842.7T patent/DK2231689T3/en active
- 2009-01-15 PT PT97028427T patent/PT2231689T/pt unknown
- 2009-01-15 ES ES09702842.7T patent/ES2598503T3/es active Active
- 2009-01-15 ES ES16174985.8T patent/ES2693551T3/es active Active
- 2009-01-15 CN CN200980109880.3A patent/CN101977923B/zh active Active
- 2009-01-15 EP EP09702842.7A patent/EP2231689B1/en active Active
- 2009-01-15 CA CA2711384A patent/CA2711384C/en active Active
-
2013
- 2013-12-25 JP JP2013266910A patent/JP2014058567A/ja not_active Withdrawn
-
2016
- 2016-10-19 CY CY20161101041T patent/CY1118104T1/el unknown
-
2018
- 2018-10-29 HR HRP20181774TT patent/HRP20181774T1/hr unknown
- 2018-10-30 CY CY20181101120T patent/CY1121364T1/el unknown